Equities

Agape ATP Corp

ATPC:NAQ

Agape ATP Corp

Actions
Health CareHealth Care Providers
  • Price (USD)1.92
  • Today's Change0.00 / 0.00%
  • Shares traded95.36k
  • 1 Year change-98.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. The Company offers four series of products: ATP Zeta Health Program, ENERGETIQUE, BEAUNIQUE and E.A.T.S. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake and unhealthy lifestyles. ENERGETIQUE series consists of the energy mask series, hyaluronic acid and mousse facial cleanser. Its BEAUNIQUE product series focuses on the research of its diet’s impact on modifying gene expressions in order to address genetic variations and deliver a personalized nutrigenomic solution for every individual.

  • Revenue in USD (TTM)1.38m
  • Net income in USD-2.45m
  • Incorporated2016
  • Employees21.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ATPC:NAQ since
announced
Transaction
value
Volt Industries Sdn BhdAnnounced08 Nov 202308 Nov 2023Announced52.38%--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biomerica Inc5.41m-5.98m5.33m63.00--0.8093--0.9854-0.3554-0.35540.32180.39180.45662.176.4985,920.63-50.43-44.68-61.13-51.7311.2314.11-110.44-63.822.43--0.00--1.420.810916.27---7.64--
Aethlon Medical, Inc.0.00-11.50m5.44m14.00--0.6239-----3.87-3.870.000.62510.00----0.00-84.49-76.25-98.84-85.78-------2,246.87----0.00---100.00---1.43------
Reflect Scientific Inc1.73m-53.09k5.82m7.00--2.9575.523.36-0.0006-0.00060.02030.0230.71970.846317.05247,638.60-2.2011.10-2.5913.2158.1962.48-3.0610.005.68--0.00---47.09-6.99-613.46------
Predictive Oncology Inc1.75m-14.04m5.87m34.00--1.23--3.36-3.36-3.360.41580.71710.11081.454.2851,425.29-88.98-91.80-121.17-126.2960.2364.64-802.93-1,419.991.37--0.0634--18.244.7545.67--5.44--
Venus Concept Inc69.81m-49.93m6.24m304.00--1.69--0.0894-8.38-8.3811.920.51030.7511.032.25229,634.90-53.53-32.71-82.19-44.0168.3968.16-71.28-48.501.30-2.750.9133---23.2628.3114.76---35.08--
Sharps Technology Inc0.00-8.21m6.73m3.00--0.9329-----0.4944-0.49440.000.25240.00-------75.56---100.97----------0.6446--0.00-------112.12------
Biotricity Inc12.24m-18.28m6.74m55.00------0.5502-1.74-1.741.18-1.272.121.678.08222,624.00-248.61-269.25----71.8958.93-117.41-258.940.106-0.6408----25.1597.8223.57------
Caduceus Software Systems Corp0.00-117.60k7.14m0.00---------0.0004-0.00040.00-0.00040.00-------402.19-11,090.31---------------76.88---------20,519.89------
Sigyn Therapeutics Inc0.00-3.70m7.27m5.00---------3.08-3.080.00-2.910.00----0.00-1,085.72-493.15-----------10,223.960.0247-2.09---------41.51------
Agape ATP Corp1.38m-2.45m7.39m21.00--2.29--5.36-0.6396-0.63960.35990.83660.44648.2536.6665,621.91-78.78---111.56--64.23---176.47--4.66--0.0225---22.92---24.61------
Bioelectronics Corp1.61m-289.82k7.41m9.00------4.60-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Nexalin Technology Inc150.16k-5.40m7.42m6.00--3.93--49.39-0.7261-0.72610.02020.17810.04460.167911.5325,026.67-160.37---202.23--82.94---3,598.50--4.89--0.00---91.62---173.80------
Neurometrix Inc4.38m-7.94m7.74m26.00--0.445--1.77-5.50-5.502.918.580.21021.158.53168,600.80-38.06-23.24-40.80-27.2660.1959.17-181.03-48.8810.71--0.00---28.52-18.18-47.84--5.03--
Dror Ortho-Design Inc0.00-5.63m7.88m4.00--4.75-----0.012-0.0120.000.00340.00-------577.48-140.50-1,394.24---------118,188.00----0.00-------1,896.02------
Guided Therapeutics Inc38.00k-2.39m9.05m4.00------238.11-0.0444-0.04440.0007-0.08290.02110.03658.449,500.00-120.81-136.13----42.1129.39-5,721.05-3,666.670.0679-7.58----653.8511.4524.40------
Precipio Inc16.72m-3.83m9.29m51.00--0.7603--0.5556-2.68-2.6811.738.240.908917.1216.80327,843.10-20.82-44.98-27.94-58.6839.0828.80-22.90-118.070.590-192.590.0517--61.4639.6252.04--5.37--
Data as of Sep 20 2024. Currency figures normalised to Agape ATP Corp's reporting currency: US Dollar USD

Institutional shareholders

54.47%Per cent of shares held by top holders
HolderShares% Held
EP Wealth Advisors LLCas of 30 Jun 20242.09k54.35%
Geode Capital Management LLCas of 30 Jun 20241.72k0.05%
UBS Securities LLCas of 30 Jun 20241.06k0.03%
G1 Execution Services LLCas of 30 Jun 2024952.000.03%
Virtu Americas LLCas of 30 Jun 2024795.000.02%
Two Sigma Securities LLCas of 30 Jun 20240.000.00%
Citadel Securities LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.